Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04092673 · ClinicalTrials.gov registry record · Phase 1
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
A Phase 1 study of Solid Tumor, Adult, sponsored by Effector Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 14
- Study locations
NCT04092673: Recruiting Phase 1 study of Solid Tumor, Adult, sponsored by Effector Therapeutics.
NCT04092673 is a Phase 1 study of Solid Tumor, Adult that is actively recruiting participants, run by Effector Therapeutics. The registered enrollment target is 30 participants, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (84% lower). The trial reports 14 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04092673, a Phase 1 study of Solid Tumor, Adult, is actively recruiting participants, sponsored by Effector Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 14
- Study locations
Study Summary
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Fulvestrant
- DRUG Abemaciclib
- DRUG Sotorasib
- DRUG eFT226
Study Locations (14)
California
- University of Southern California - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Stanford University - Palo Alto
New York
- Memorial Sloan Kettering Cancer Center- Commack - Commack
- Memorial Sloan Kettering Cancer Center- Westchester - Harrison
- Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer Care - New York
Texas
- MD Anderson Cancer Center - Houston
- New Experimental Therapeutics of San Antonio - NEXT Oncology - San Antonio
Michigan
- START Midwest - Grand Rapids
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
New Jersey
- Memorial Sloan Kettering Cancer Center- Monmouth - Middletown
Ohio
- University of Toledo Medical Center - Toledo
Virginia
- Virginia Cancer Specialists - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-10-25 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 1 |
What NCT04092673 shows while recruiting
NCT04092673 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.
NCT04092673 lists 14 locations in 8 states (California, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT04092673 about?
NCT04092673 is a clinical study titled "Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies". This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
What is the current status of trial NCT04092673?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-10-25. Estimated completion is 2025-03-31.
What conditions does trial NCT04092673 study?
This clinical trial studies the following conditions: Solid Tumor, Adult.
What interventions are being tested in trial NCT04092673?
The interventions under investigation include: Trastuzumab (DRUG), Fulvestrant (DRUG), Abemaciclib (DRUG), Sotorasib (DRUG), eFT226 (DRUG).
Who is sponsoring clinical trial NCT04092673?
This trial is sponsored by Effector Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04092673 being conducted?
This trial has 14 study locations across California, Michigan, Nevada, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04092673's enrollment target sits among peer trials
30 68th of 72 higher than 5 of 72 other Solid Tumor, Adult trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI